Menu

Privacy Policy

ON TARGET LABORATORIES

Last Modified: [04/26/2021]

This Privacy Policy (“Privacy Policy”) is designed to help website users (“You”)  understand what information On Target Laboratories, Inc. (the “Company,” “we,” “ours,” “us”) gathers, how we use it, what we do to protect it, and to assist you in making informed decisions when using service which can be accessed via our website (“Sites”). Unless otherwise indicated below, this Privacy Policy applies to any website that references this Privacy Policy, any Company website, as well as any data the Company may collect across partnered and unaffiliated sites.

I. CONSENT

By accessing our Sites, you accept our Privacy Policy and Terms of Use, and you consent to our collection, storage, use and disclosure of your personal information as described in this Privacy Policy. In addition, by using our Sites, or services across partnered and unaffiliated sites, you are accepting the policies and practices described in this Privacy Policy. Each time you visit our website, or use the Sites, and any time you voluntarily provide us with information, you agree that you are consenting to our collection, use and disclosure of the information that you provide, and you are consenting to receive emails or otherwise be contacted, as described in this Privacy Policy. Whether or not you register or create any kind of account with us, this Privacy Policy applies to all users of the website and the Sites. If you do not agree with the terms of this Privacy Policy, please do not use the Service.

II. INFORMATION WE COLLECT

We may collect both “Automatic Information” and “Personal Information” about you. “Automatic Information” includes information that cannot be used to personally identify you, such as anonymous usage data, general demographic information we may collect, referring/exit pages and URLs, platform types, preferences you submit and preferences that are generated based on the data you submit and number of clicks. “Personal Information” is information you provide to us, such as your name, occupation, mailing address and email address.

In addition, we may also track information provided to us by your browser or by our mobile application when you view or use the Sites, such as the website you came from (known as the “referring URL”), the type of browser you use, the device from which you connected to the Sites, the time and date of access, and other information that does not personally identify you. We use this information for, among other things, the operation of the Sites, to maintain the quality of the Sites, to provide general statistics regarding use of the Sites and for other business purposes. We track this information using cookies, or small text files which include an anonymous unique identifier. Cookies are sent to a user’s browser from our servers and are stored on the user’s computer hard drive. Sending a cookie to a user’s browser enables us to collect Automatic Information about that user and keep a record of the user’s preferences when utilizing our services, both on an individual and aggregate basis. The Company may use both persistent and session cookies; persistent cookies remain on your computer after you close your session and until you delete them, while session cookies expire when you close your browser. Persistent cookies can be removed by following your Internet browser help file directions. If you choose to disable cookies, some areas of the Sites may not work properly.

III. HOW WE USE AND SHARE INFORMATION

Personal Information:

In general, we do not sell, trade, rent or otherwise share your Personal Information with third-parties without your consent. We may disclose your Personal Information if required to do so by law or if you violate our Terms of Use.

Automatic Information:

In general, we use Automatic Information to help us improve the Sites and customize the user experience. We also aggregate Automatic Information in order to track trends and analyze use patterns of the Sites. This Privacy Policy does not limit in any way our use or disclosure of Automatic Information and we reserve the right to use and disclose such Automatic Information to our partners, advertisers and other third-parties at our sole discretion.

IV. HOW WE PROTECT INFORMATION

We implement reasonable precautions in order to help protect your Personal Information. However, these measures do not guarantee that your information will not be accessed, disclosed, altered or destroyed by breach of such precautions. By using our Sites, you acknowledge that you understand and agree to assume these risks.

V. YOUR RIGHTS TO OPT OUT

When we send a promotional communication to a user via the website hosting provider, the user can opt out of further promotional communications by following the unsubscribe instructions provided in each promotional e-mail.

VI. LINKS TO OTHER WEBSITES

As part of the Sites, we may provide links to or compatibility with other websites or applications. However, we are not responsible for the privacy practices employed by those websites or the information or content they contain. This Privacy Policy applies solely to information collected by us through the Sites. Therefore, this Privacy Policy does not apply to your use of a third-party website accessed by selecting a link via our Sites. To the extent that you access or use the Sites through or on another website or application, then the privacy policy of that other website or application will apply to your access or use of that site or application. We encourage our users to read the privacy statements of other websites before proceeding to use them.

VII. SOCIAL MEDIA GUIDELINES

We value your interest and participation. Because we work in a regulated industry, however, when you engage with us on any of the Company’s social media channels you are agreeing to abide by these Social Media Guidelines. These are a supplement to any other disclosures provided, such as those discussing Privacy or Terms of Use, including those of the platform itself (e.g. Twitter, LinkedIn, etc.).

Our posts are informational only and are not to be considered health or medical advice. You should also not consider any comments or posts by others to be a substitute for advice from your own doctor.  Always talk to a medical professional to address questions about a medical condition.

We have set up our social accounts to share news and information with you. We do not promise to respond to comments or links you may post but do reserve the right to remove a comment or link at our sole discretion.  Reasons we might remove them include:

  • The comment mentions a specific product – whether ours or those of another company- and does not include all the information required by the government;
  • The comment includes false, misleading, inaccurate or deceptive information;
  • The comment contains language, images or links that are defamatory, profane, obscene, or disparaging of others’ race, gender, religion, age or lifestyle, or it contains threats/ messages condoning violence or illegal behaviors; or
  • The comment is off-topic or is using our space to advertise or promote other sites, products or services or to solicit followers.

If you are a minor, do not post or share comments without the permission of a parent or legal guardian.

Please be cautious about sharing details about your own healthcare or providing advice or suggestions to others. If you share personal information about other people, you are representing to us that you have the legal right and/or permissions to do so.

Comments or content posted by any person other than the Company are solely the views, opinions and responsibility of the person expressing them, and do not necessarily reflect our views or opinions. The Company does not guarantee the accuracy or reliability of third-party materials.

On occasion, the Company may link to another website or social media account not generated by the Company. Doing so is not an endorsement of that site, and Company has no responsibility to independently validate the accuracy or content on the third-party account.

If you are a medical professional and require further information about the Company, clinical research or clinical trials we are conducting, please send an e-mail info@ontargetlabs.com.

If you are a patient and require additional information about the Company, clinical research or clinical trials we are conducting, please contact your physician.

VIII. NOTICE TO CALIFORNIA RESIDENTS

If you are a California resident, California Civil Code Section 1798.83 permits you to request information regarding the disclosure of your personal information by certain members of Company to third-parties for the third parties’ direct marking purposes. To make such a request, please send an email to info@ontargetlabs.com.

IX. DO NOT TRACK

Do Not Track Mechanisms.  Because of the changing state of technology and indecision within the industry regarding the meaning of Do Not Track requests, we currently do not make any guarantee that we will honor Do Not Track requests.

X. CHILDREN UNDER THE AGE OF EIGHTEEN

Our Site is not intended for children or minors under the age of eighteen years without the permission of a parent or guardian. If you believe that a child has submitted personal information on or through our Sites without the consent and supervision of a parent or guardian, please contact us using the information provided below so that we can take appropriate action.

XI. CHANGES TO OUR PRIVACY POLICY

The Company reserves the right to change this Privacy Policy and our Terms of Use at any time. If we decide to change this Privacy Policy, we will post these changes on this page so that you are always aware of what information we collect, how we use it, and under what circumstances we disclose it. Any such modifications become effective upon your continued access to and/or use of the Sites. It is your sole responsibility to check this website from time to time to view any such changes to the terms of this Privacy Policy. If you do not agree to any changes, if and when such changes may be made to this Privacy Policy, you must cease access to this website. If you have provided your email address to us, you give us permission to email you for the purpose of notification as described in this Privacy Policy. The date of the most version of this Privacy Policy is at the top of this Privacy Policy.

XII. CONTACT US & WITHDRAWING CONSENT

If you have any questions regarding this Privacy Policy or the practices of this Site, or wish to withdraw your consent for the continued collection, use or disclosure of your Personal Information, please contact us by sending an email to info@ontargetlabs.com.

On Target Laboratories
1281 Win Hentschel Blvd.
West Lafayette, IN 47906
(765)588-4547
info@ontargetlabs.com

INDICATION

CYTALUX® is an FDA approved optical imaging agent indicated as an adjunct for intraoperative identification of:

  • Malignant lesions in adult patients with ovarian cancer.
  • Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung.
IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
Infusion-Related Reactions
Adverse reactions including nausea, vomiting, abdominal pain, flushing, hypersensitivity, elevation in blood pressure, dyspepsia, and chest discomfort were reported in patients receiving CYTALUX in clinical studies. A total of 17% of patients experienced reactions during administration of CYTALUX.

Important Safety Information and Indication for Cytalux® Important Safety Information for Cytalux®

INDICATION AND USAGE
CYTALUX® is an FDA approved optical imaging agent indicated as an adjunct for intraoperative identification of:

  • Malignant lesions in adult patients with ovarian cancer.
  • Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung.

IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Infusion-Related Reactions
Adverse reactions including nausea, vomiting, abdominal pain, flushing, hypersensitivity, elevation in blood pressure, dyspepsia, and chest discomfort were reported in patients receiving CYTALUX in clinical studies. A total of 17% of patients experienced reactions during administration of CYTALUX. Reactions typically occurred within 15 minutes of the start of infusion. CYTALUX infusion interruption or discontinuation due to adverse reactions occurred in 11% of all patients. Treatment with antihistamines and/or anti-nausea medication may be used. If an adverse reaction occurs during administration, the infusion can be interrupted and resumed after treatment of the reaction.

Risk of Misinterpretation
Errors may occur with the use of CYTALUX during intraoperative fluorescence imaging to detect ovarian cancer and lesions in the lung, including false negatives and false positives. Non-fluorescing tissue in the surgical field does not rule out the presence of ovarian cancer or lesions in the lung. Fluorescence may be seen in normal tissues including bowel, kidneys, lymph nodes, lungs, and inflamed tissue.

Embryo-Fetal Toxicity
Based on its mechanism of action, CYTALUX may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Verify pregnancy status of females of reproductive potential prior to initiating CYTALUX treatment.

Risk of Pafolacianine Aggregation and Infusion Reactions
Use of the incorrect diluent to prepare the CYTALUX infusion solution can cause the aggregation of pafolacianine; aggregation may induce infusion reactions such as nausea, vomiting, abdominal pain or rash.  Use only 5% Dextrose Injection to prepare the CYTALUX infusion solution. Do not use other diluents.

DRUG INTERACTIONS
Use of folate, folic acid, or folate-containing supplements may reduce binding of pafolacianine to folate receptors and could reduce the detection of lesions with CYTALUX. Avoid administration of folate, folic acid, or folate-containing supplements within 48 hours before administration of CYTALUX

ADVERSE REACTIONS
The safety of CYTALUX was evaluated in four open label clinical studies, two studies (N = 44 and N = 150) in patients with ovarian cancer and two studies (N = 100 and N = 112) in patients with known or suspected cancer in the lung. A total of 406 patients received 0.025 mg/kg of CYTALUX via intravenous administration.

Adverse reactions that occurred in ≥ 1% of patients were: nausea (13%), vomiting (5%), abdominal pain (2%), flushing (2%), other infusion-related reactions (2%), hypersensitivity (2%), elevation in blood pressure (1%), dyspepsia (1%), and chest discomfort (1%). Adverse reactions occurred during the administration of CYTALUX in 17% of patients.

See full Prescribing Information to learn more.